Nektar Therapeutics (NKTR) : Duquesne Family Office added new position in Nektar Therapeutics during the most recent quarter end. The investment management firm now holds 572,100 shares of Nektar Therapeutics which is valued at $8,243,961 , the company said in a statement filed on Nov 14, 2016 with the SEC.Nektar Therapeutics makes up approximately 0.75% of Duquesne Family Office’s portfolio.
Other Hedge Funds, Including , Millennium Management boosted its stake in NKTR in the latest quarter, The investment management firm added 392,144 additional shares and now holds a total of 439,503 shares of Nektar Therapeutics which is valued at $6,333,238. Nektar Therapeutics makes up approx 0.01% of Millennium Management’s portfolio.Leisure Capital Management reduced its stake in NKTR by selling 103 shares or 0.68% in the most recent quarter. The Hedge Fund company now holds 15,043 shares of NKTR which is valued at $187,135. Nektar Therapeutics makes up approx 0.18% of Leisure Capital Management’s portfolio.Great West Life Assurance Co Can boosted its stake in NKTR in the latest quarter, The investment management firm added 7,569 additional shares and now holds a total of 183,682 shares of Nektar Therapeutics which is valued at $2,206,021. Nektar Therapeutics makes up approx 0.01% of Great West Life Assurance Co Can’s portfolio.Rathbone Brothers Plc reduced its stake in NKTR by selling 2,000 shares or 11.24% in the most recent quarter. The Hedge Fund company now holds 15,800 shares of NKTR which is valued at $206,980. Nektar Therapeutics makes up approx 0.01% of Rathbone Brothers Plc’s portfolio. Howe Rusling Inc sold out all of its stake in NKTR during the most recent quarter. The investment firm sold 60 shares of NKTR which is valued $953.
Nektar Therapeutics closed down -0.03 points or -0.21% at $13.94 with 11,95,037 shares getting traded on Monday. Post opening the session at $13.74, the shares hit an intraday low of $13.7 and an intraday high of $14.14 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Nektar Therapeutics reported $-0.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Nov 3, 2016. Analyst had a consensus of $-0.36. The company had revenue of $36.30 million for the quarter, compared to analysts expectations of $31.50 million. The company’s revenue was down -39.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.06 EPS.
Many Wall Street Analysts have commented on Nektar Therapeutics. Nektar Therapeutics was Initiated by Aegis Capital to “Buy” on Nov 8, 2016. Nektar Therapeutics was Resumed by Brean Capital to “Buy” on Sep 30, 2016.
Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Companys research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.